Memo Therapeutics CEO Erik van den Berg reflects on the strategies and skills needed to build company resilience and navigate ...

It wouldn't be accurate to say that surgeon-turned-healthcare investment banker and consultant Dr. Ali Pashazadeh traded his scalpels for spreadsheets. In fact, he still wields a scalpel quite ...

Novo Nordisk SVP Blandine Lacroix shares her career story and discusses the importance of prioritizing your own personal ...

Created exclusively for the leaders of new and emerging biopharma firms, The Business of Biotech tackles organizational, funding, HR, regulatory, production and CMC considerations with insight from ...

Teva Pharmaceuticals "pivot to growth" strategy under CEO Richard Francis aims to use a combination of biosimilars, generics, ...

Life sciences legal departments can do more to improve financial efficiency across an organization. This article includes ...

Terns Pharmaceuticals aims to improve upon currently marketed therapies in CML and obesity, using internally discovered small ...

Cybin CEO Doug Drysdale discusses learnings from psychedelic drug clinical trial missteps, provides examples of the benefits ...

Inozyme's CEO and chairman Douglas Treco shares his thoughts about the rousing success of the Orphan Drug Act, but cautions rare disease drug developers against sky high and inaccessible drug pricing ...